男性泌尿生殖道性病感染的检验与疗效分析

目的分析男性泌尿生殖道感染的4种与性传播有关的病原体的分离及治疗情况。方法306例男性泌尿生殖道标本应用免疫层析法检测沙眼衣原体（Ct）抗原，培养法检查淋病奈瑟菌（Ngo）、解脲脲原体（uu）和人型支原体（Mh）。病原体阳性者按规范疗程治疗后进行复查。结果306例标本中4种病原体的总阳性率为25．49％（78／306），其中Uu、Mh、Ct、Uu＋Mh、Uu＋Ct以及Ng0的阳性率分别为13．40％、0．33％、1．31％、6．21％、1．31％和2．94％。uu和Mh药敏试验结果显示，敏感率较高的抗菌药物有强力霉素（92．30％）、美满霉素（90．76％）、交沙霉素（75．38％）和加替沙星（72．31％）。UU和Mh感染者用强力霉素治疗2周有效率为73．33％，治疗3周有效率为93．33％。结论Uu是男性泌尿生殖道感染最常见的病原体，其次是Mh、Ct和Ngo的感染率都比较低。该地区非淋菌性尿道炎的经验治疗首选强力霉素，并且采用3周疗程有效率更高。地方性的支原体耐药性监测分析及治疗效果对比研究对指导临床合理用药意义重大。

Analysis on detection for male urogenital tract infection and its treatment effect

Objective To analyse the isolation and treatment situation of 4 kinds of sexually tranmitted patho- gens in male urogenital tract infection. Methods 306 male urogenital tract specimens were detected chlamydia tracho- matis antigen（CO by the immunochromatographie method, neisseria gonorrhoeae（Ngo）, Ureaplasma ureaiyticum （Uu） and Mycoplasma hominis（Mh） by the culture method. The cases with positive pathogens were treated by standard treatment course. Then the reexamination was conducted. Results Among 306 specimens,the total positive rate of 4 kinds of pathogens was 25.49 % （78/306）, the positive rates of Uu, Mh, Ct, Uu ＋ Mh and Uu ＋ Ct were 3.40 %,0.33 %, 1.31%, 6.21%, 11 31% and 2.94 % respectively. The drug sensitivity test results of Uu and Mh re- vealed that the higher sensitive antibacterial drugs were doxycyclin （92. 30%）, minocin （90. 76%）, josanmycin （75.38 % ） and gatifloxacin（72.31 % ）. The efffective rates of 2-week and 3-week doxyeycline treatment were 73.33 and 93.33 % respectively. Conclusion Uu is the most common pathogen in male urogenital tract infection, followed by Mh. The infection rate of Ct and Ngo is very low. The empirical therapy of non-Ngo urethritis in this area is doxy- cycline as the first choice. Furthermore;the 3 week course of treatment has higher effective rate. The local drug re- sistance monitoring of mycoplasma and the comparative study of the treatment effects have very important signifi- cance to guide the clinical rational drug use.